Peptides
P21 peptide
The neurotrophic research compound P21/P021 has animal and cell evidence; unrelated p21 proteins must not be counted as support.
Preclinical peptide-mimetic research; no human treatment evidence in reviewed studies
Also known as: P21 · P021 · P-21
Practical use
Reviewed practical notes
- Check the identity
- P21/P021 is not p21/CDKN1A or RAS-p21.
- Keep negative findings
- The later mouse study did not reproduce all anticipated benefits.
- Do not borrow human indexing
- Human-derived cells do not turn an experiment into a patient trial.
Overview
Here P21 means the modified CNTF-derived compound also called P021. The original paper calls it P21; a later primary methods section identifies P021 using the same chemical shorthand and an adamantane-containing modification. This is different from the cell-cycle protein p21/CDKN1A or RAS-p21.
Risks and limitations
The reviewed experiments do not establish human cognitive benefit, clinical safety or the identity of a commercial P21 preparation. A human neuroblastoma cell line is laboratory material, not evidence that patients received the treatment.
How to read this
The findings are mixed across models. Early work reported memory-related improvements in normal mice. A later disease-model study found cellular improvements that did not translate into the anticipated brain changes in mice. That gap is central to the evidence.
Research explained
Original P21 mouse study
Who was studied
Normal adult mice in neurogenesis and learning experiments.
What was found
The study reported improvements in selected learning and memory tasks and measures of newly generated neurons.
What it cannot establish
The abstract does not provide enough detail for a complete bias assessment. These were mouse outcomes, not demonstrated human memory improvement.
Read the original studyP021 in CDKL5-deficiency models
Who was studied
A human neuroblastoma cell line lacking CDKL5 and genetically modified mice.
What was found
Some cellular deficits improved. In mice, treatment did not increase brain BDNF or improve the main neuroanatomical defects, and behavioral benefit was limited.
What it cannot establish
The cell and animal findings must be reported separately. Neither establishes a therapy for human CDKL5 deficiency or healthy cognitive enhancement.
Read the original studyResolve the name before using the paper
The primary methods identify P021 as a modified CNTF-derived molecule and cite the original P21 study. Research on unrelated p21 proteins, fluorescent sensors or peptide hydrogels cannot support this compound’s clinical claims.
Supporting sourceSources
2024 P021 cell and mouse study
2024 primary methods confirming molecular identity
Sources checked 2026-10-01.
General education; not a personal treatment plan.